Showing 20 of 183 recruiting trials for “hepatocellular-carcinoma”
Neoadjuvant Combination Therapy of Lenvatinib and TACE for Transplant-Eligible Large Hepatocellular Carcinoma Patients
👨⚕️ Maen Abdelrahim, MD, The Methodist Hospital Research Institute📍 1 site📅 Started Jun 2022View details ↗
A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors
👨⚕️ Weijia Fang, M.D, The First Affiliated Hospital, Zhejiang University📍 1 site📅 Started May 2022View details ↗
RecruitingNCT05534906 ↗
The Detection of Small Early Liver Cancer With Natural History Follow up
A National Phase II Study of Proton Therapy in Hepatocellular Carcinoma
👨⚕️ Britta Weber, MD PhD, Danish Center of Particle Therapy📍 3 sites📅 Started Apr 2022View details ↗
Liver Cancer Disparities in American Indian and Alaska Native Persons
Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcinoma
T-Cell Therapy (ECT204) in Adults With Advanced HCC
RecruitingNCT05287464 ↗
International Multicentric Study ARON-1
18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
RecruitingNCT05363657 ↗
International REgistry of COnservative or Radical Treatment of Localized Kidney Tumors
👨⚕️ Andrea Minervini, Prof., Dipartimento di Medicina Clinica e Sperimentale Via o Piazza Largo Brambilla 3 - 50134 Firenze (Italy)📍 37 sites📅 Started Jan 2022View details ↗
A Phase 2, Open-Label Study of ABSK-011 Combined Atezolizumab or SOC in HCC Patients
GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor Malignancies
Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
A Study of GC101 TIL in Advanced Hepatobiliary-Pancreatic Cancers (10hospital)
RecruitingNCT04792801 ↗
PET TDM FDG-Choline as a Decision-making Tool for Routine Care on the Liver Transplant List for HCC
RecruitingNCT05248412 ↗
The Long-term Spill-over Impact of COVID-19 on Health and Healthcare of People With Non-communicable Diseases
Artificial Intelligence vs. LIRADS in Diagnosing HCC on CT
Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
Neo-TACE-HAIC for High-risk BCLC A Stage HCC (NeoconceptA)
RecruitingNCT04712305 ↗
Urine Omics Predicting IO Therapy Responses in mRCC Patients
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →